Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration.

Fiche du document

Auteurs
Discipline
Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/bjophthalmol-2018-312318

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30030393

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1468-2079

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A0255087CC949

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/

Mots-clés 0

Aged; Angiogenesis Inhibitors/administration & dosage; Antidepressive Agents/therapeutic use; Depression/complications; Depression/diagnostic imaging; Drug Therapy, Combination; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Intravitreal Injections; Male; Prospective Studies; Ranibizumab/administration & dosage; Receptors, Vascular Endothelial Growth Factor/administration & dosage; Recombinant Fusion Proteins/administration & dosage; Retina/diagnostic imaging; Retreatment/methods; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Wet Macular Degeneration/complications; Wet Macular Degeneration/diagnosis; Wet Macular Degeneration/drug therapy; angiogenesis; degeneration; drugs; medical treatment; retina

Sujets proches En

Therapy Factors Agents, Manufacturers' Manufacturers' representatives Factors

Citer ce document

I. Mantel et al., « Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration. », Serveur académique Lausannois, ID : 10.1136/bjophthalmol-2018-312318

Métriques

Partage / Export

Résumé 0

Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD) and is also involved in the final common pathway of antidepressant medication. This study investigated the relationship between the need for anti-VEGF retreatment in patients with nAMD and antidepressant medication, and the potential impact of ocular structural factors. Data from two identical prospective 2-year treatment protocols using ranibizumab or aflibercept in a variable-dosing regimen ('Observe-and-Plan') were analysed. Retreatment requirement was compared with antidepressant medication intake (primary outcome) and a variety of ocular factors from baseline and from month 3 response (secondary outcomes), using univariate and multivariate analyses. Of the 206 included patients (227 eyes), 19 were on antidepressant medication. Their nAMD eyes significantly more often had pigment epithelium detachment (PED, p=0.04). Multivariate analysis revealed a significant association between anti-VEGF retreatment requirement and antidepressant medication use (p=0.027), as well as thicker central retinal thickness at month 3 (p

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Sur les mêmes disciplines

Exporter en